At the extraordinary general meeting in BICO Group AB (publ) (the “Company" or “BICO”), held on November 17, 2021, the following resolutions were passed.

  • The extraordinary general meeting resolved, in accordance with the nomination committee’s proposal, to elect Susan Tousi as a new member of the board of directors of BICO. The board of directors therefore consists of Carsten Browall (Chairman), Aristotelis Nastos, Bengt Sjöholm, Christian Wildmoser, Erik Gatenholm, Helena Skåntorp, and Susan Tousi, all for the period until the end of the next annual general meeting.
  • The extraordinary general meeting resolved, in accordance with the proposal by the board of directors, to authorise the board of directors, for the period until the end of the next annual general meeting, at one or several occasions and with or without deviation from the shareholders’ preferential rights, to resolve on a new issue of shares of series B. The authorisation may be utilised for new issues of shares of series B, which may be made with provisions regarding contribution in cash, in kind or through set-off corresponding to a dilution of not more than 20 per cent of the registered share capital in the Company at the time of the issue resolution. The subscription price shall be determined on market terms and conditions.
  • Deviations from shareholders’ preferential rights should only be possible in connection with acquisitions of operations, companies, participations in companies and other rights associated therewith or for the Company’s continued expansion. If the Board of Directors resolves on an issue with deviation from the shareholders’ preferential rights, the rationale should be that the Board quickly and efficiently may issue shares in the Company to be utilised as means of in-kind payment or the right to offset debt or to in a flexible and cost-efficient manner raise capital to use as means of payment.
  • The new authorisation replaces the existing authorisation from the annual general meeting held on April 26, 2021.

Approximately 72 per cent of the votes were represented at the extraordinary general meeting.

For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70830 0890
Email: il@bico.com

This information was submitted for publication, through the agency of the contact person set out above, on November 17, 2021 at 12:40 (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com